Some topics about AdVita: www.advita-lifescience.com
AdVita Lifescience GmbH, Germany
We develop effective products and strategies to improve the therapy and diagnosis of rare lung diseases.
To do this, we use a drug with the active ingredient Aviptadil for inhalative/topical therapy.
Aviptadil (vasoactive intestinal peptide (VIP)) is an endogenous peptide that has already been approved for another indication (erectile dysfunction) with an excellent safety profile.
The preclinical for inhalation therapy is available. Studies and case reports show an excellent effectiveness and tolerance of the drug.
Patients with sarcoid and related diseases (e.g. beryllium disease) have already benefited significantly from treatment in off-label use, so that many health insurance companies cover the costs of the therapy.
The simple application takes place with a nebulizer of the latest generation.
PRESS RELEASE (Supplement to Post # 38719)
Geneva, Switzerland and Gundelfingen, Germany, April 22, 2021 - RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF)
Headline:
Relief and AdVita announce start of phase 2 study with inhaled RLF-100 formulation for the prevention of COVID-19-related acute respiratory distress syndrome
(Study - sponsored i.a. by well-known doctors - that is being carried out at major medical centers in Switzerland.)
[………………] inter alia:
Today Relief gives an update on the planned clinical development of RLF-100 in Europe also:
Relief is currently preparing a phase 2b / 3 study in Europe with intravenous RLF100 with COVID-19 patients. Once Relief's partner NeuroRx has submitted an Emergency Use Authorization (EUA) application to the US Food and Drug Administration (FDA) and a decision has been made, Relief will be on the best steps to take for further development of intravenous RLF-100 in Europe and other regions. Relief continues to see great value in RLF-100 in helping patients with COVID-19-related lung damage and hopes that an EUA of RLF-100 can accelerate the clinical trial of RLF-100 in Europe. The clinical development of intravenous RLF-100 in non-COVID-19-induced ARDS is also being considered.
